×
About 65,448 results

ALLMedicine™ Pancreatic Cancer Center

Research & Reviews  30,963 results

Increased myocellular lipid and IGFBP-3 expression in a pre-clinical model of pancreati...
https://doi.org/10.1002/jcsm.12699
Journal of Cachexia, Sarcopenia and Muscle; Cole CL, Bachman JF et. al.

May 7th, 2021 - Skeletal muscle wasting (SMW) in cancer patients is associated with increased morbidity, mortality, treatment intolerance and discontinuation, and poor quality of life. This is particularly true for patients with pancreatic ductal adenocarcinoma (...

CDK5 positively regulates Notch1 signaling in pancreatic cancer cells by phosphorylation.
https://doi.org/10.1002/cam4.3916
Cancer Medicine; Chu Q, Wang L et. al.

May 7th, 2021 - The marked overexpression of cyclin-dependent kinase 5 (CDK5) or Notch1 receptor, which plays critical roles in pancreatic ductal adenocarcinoma (PDAC) development, has been detected in numerous PDAC cell lines and tissues. Although, a previous st...

Helios serves as a suppression marker to reduce regulatory T cell function in pancreati...
https://doi.org/10.1007/s12026-021-09200-9 10.1111/imr.12160 10.4049/jimmunol.0904028
Immunologic Research; Liu MF, Jin C et. al.

May 7th, 2021 - Destabilizing and reprogramming regulatory T (Treg) cells have become a potential strategy to treat tumor. Mounting evidence indicates that the transcription factor Helios is required for the stable differentiation of Treg lineage. Hence, we inves...

A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Anti...
https://doi.org/10.1007/s11095-021-03045-5 10.3322/caac.21590 10.1016/S0140-6736(10)62307-0 10.1007/s11095-016-1902-8 10.1093/annonc/mdj941 10.1016/0006-2952(94)90554-1 10.2217/pgs-2017-0034 10.1200/JCO.2003.09.140 10.1186/s13000-014-0214-8 10.1016/j.jconrel.2016.07.028 10.1126/science.1095833 10.3390/pharmaceutics6010137 10.2165/00003088-200342050-00002 10.1158/1078-0432.CCR-16-3193
Pharmaceutical Research; Matsumoto T, Komori T et. al.

May 7th, 2021 - The clinical application of gemcitabine (GEM) is limited by its pharmacokinetic properties. The aim of this study was to characterize the stability in circulating plasma, tumor targeting, and payload release of liposome-encapsulated GEM, FF-10832....

see more →

Guidelines  89 results

Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077959
Pancreas Okusaka T, Nakamura M et. al.

Mar 6th, 2020 - Clinical Practice Guidelines for Pancreatic Cancer were first published in 2006 by the Japan Pancreas Society, and they were revised in 2009, 2013, and 2016. In July 2019, the Clinical Practice Guidelines for Pancreatic Cancer 2019 were newly revi...

Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practic...
https://doi.org/10.1016/j.prro.2019.06.016
Practical Radiation Oncology; Palta M, Godfrey D et. al.

Sep 2nd, 2019 - This guideline systematically reviews the evidence for treatment of pancreatic cancer with radiation in the adjuvant, neoadjuvant, definitive, and palliative settings and provides recommendations on indications and technical considerations. The Am...

Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recomm...
https://doi.org/10.1001/jama.2019.10232
JAMA , Owens DK et. al.

Aug 6th, 2019 - Pancreatic cancer is an uncommon cancer with an age-adjusted annual incidence of 12.9 cases per 100 000 person-years. However, the death rate is 11.0 deaths per 100 000 person-years because the prognosis of pancreatic cancer is poor. Although its ...

Screening for Pancreatic Cancer Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
https://jamanetwork.com/journals/jama/fullarticle/2740726
JAMA

Aug 5th, 2019 - Importance Pancreatic adenocarcinoma is the third most common cause of cancer death among men and women in the United States. Objective To systematically review benefits and harms of screening for pancreatic adenocarcinoma to inform the US Prev...

see more →

Drugs  91 results see all →

Clinicaltrials.gov  32,877 results

Increased myocellular lipid and IGFBP-3 expression in a pre-clinical model of pancreati...
https://doi.org/10.1002/jcsm.12699
Journal of Cachexia, Sarcopenia and Muscle; Cole CL, Bachman JF et. al.

May 7th, 2021 - Skeletal muscle wasting (SMW) in cancer patients is associated with increased morbidity, mortality, treatment intolerance and discontinuation, and poor quality of life. This is particularly true for patients with pancreatic ductal adenocarcinoma (...

CDK5 positively regulates Notch1 signaling in pancreatic cancer cells by phosphorylation.
https://doi.org/10.1002/cam4.3916
Cancer Medicine; Chu Q, Wang L et. al.

May 7th, 2021 - The marked overexpression of cyclin-dependent kinase 5 (CDK5) or Notch1 receptor, which plays critical roles in pancreatic ductal adenocarcinoma (PDAC) development, has been detected in numerous PDAC cell lines and tissues. Although, a previous st...

Helios serves as a suppression marker to reduce regulatory T cell function in pancreati...
https://doi.org/10.1007/s12026-021-09200-9 10.1111/imr.12160 10.4049/jimmunol.0904028
Immunologic Research; Liu MF, Jin C et. al.

May 7th, 2021 - Destabilizing and reprogramming regulatory T (Treg) cells have become a potential strategy to treat tumor. Mounting evidence indicates that the transcription factor Helios is required for the stable differentiation of Treg lineage. Hence, we inves...

A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Anti...
https://doi.org/10.1007/s11095-021-03045-5 10.3322/caac.21590 10.1016/S0140-6736(10)62307-0 10.1007/s11095-016-1902-8 10.1093/annonc/mdj941 10.1016/0006-2952(94)90554-1 10.2217/pgs-2017-0034 10.1200/JCO.2003.09.140 10.1186/s13000-014-0214-8 10.1016/j.jconrel.2016.07.028 10.1126/science.1095833 10.3390/pharmaceutics6010137 10.2165/00003088-200342050-00002 10.1158/1078-0432.CCR-16-3193
Pharmaceutical Research; Matsumoto T, Komori T et. al.

May 7th, 2021 - The clinical application of gemcitabine (GEM) is limited by its pharmacokinetic properties. The aim of this study was to characterize the stability in circulating plasma, tumor targeting, and payload release of liposome-encapsulated GEM, FF-10832....

see more →

News  1,335 results

Pancreatic Cancer Surveillance in People at High Risk Not Tied to Better Outcomes
https://www.medscape.com/viewarticle/949359

Apr 15th, 2021 - NEW YORK (Reuters Health) - Surveillance of people at high hereditary risk for pancreatic ductal adenocarcinoma (PDAC) can lead to diagnosis at an earlier stage, but as yet there is no clear survival benefit, according to researchers in the Nether...

Ablative Radiation Extends Life in Unresectable Pancreatic Cancer
https://www.medscape.com/viewarticle/947758

Mar 18th, 2021 - For patients with inoperable pancreatic cancer, higher dose ablative radiation after chemotherapy induction may extend life, say investigators from Memorial Sloan Kettering Cancer Center in New York City. When delivering the radiation, adjustments...

Pegilodecakin No Aid to FOLFOX in Metastatic Pancreatic Cancer
https://www.medscape.com/viewarticle/946610

Mar 1st, 2021 - NEW YORK (Reuters Health) - Adding immunotherapy pegylated IL-10 (pegilodecakin) to folinic acid, fluorouracil and oxaliplatin (FOLFOX) in patients with advanced gemcitabine-refractory pancreatic cancer does not improve overall survival, according...

Cancer Death Rates Continue to Fall in Europe, Except For...
https://www.medscape.com/viewarticle/946288

Feb 22nd, 2021 - Cancer death rates overall continue to fall among both men and women in Europe, with the notable exception of pancreatic cancer in both sexes and lung cancer among women living in the European Union, notes an update report. "Among the major cancer...

High Cost of Pancreatic Enzymes a Barrier for Patients With Cancer
https://www.medscape.com/viewarticle/944683

Jan 25th, 2021 - Pancreatic enzyme replacement therapy (PERT) is often an essential component of the treatment regimen for patients with pancreatic cancer, but it can be very pricey. "Out-of-pocket costs for a 30-day supply of enzymes for Medicare beneficiaries ca...

see more →

Patient Education  93 results see all →